ArticleBMC cancer2025
Effective serum concentration of high-dose methotrexate therapy for osteosarcoma with dose adjustment for pharmacokinetic parameters: a retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn high-dose methotrexate (MTX) (HD-MTX) therapy, a dosage regimen utilizing the pharmacokinetic (PK) parameters of individual patients (PK method) has been developed to successfully reduce the intra- and inter-individual variability of serum MTX concentration. In this study, we evaluated the relationship between the therapeutic effect and serum MTX concentration in HD-MTX therapy performed under conditions in which the serum MTX concentration was precisely controlled using the PK method.
methodsHD-MTX therapy consisted of 1 h of rapid dosing and 5 h of maintenance dosing, with a target serum concentration of 700–1000 µmol/L 1–6 h after the start of administration. The initial MTX dose was determined based on the body surface area, and subsequent courses were determined using PK parameters calculated from changes in MTX concentration at 1, 2, 4, 6, 7, 9, 12, 24, 48, and 72 h after the start of MTX administration. The relationship between the maximum serum MTX concentration (Cmax) and mean concentration from 1 to 6 h after MTX administration [Cmean(1−6)] and efficacy was evaluated. The cut-off values for Cmax and Cmean(1−6) were the values with the best sensitivity and specificity in terms of 5-year survival in the receiver operating characteristic curve.
resultsWe included 33 patients with osteosarcoma without distant metastasis who underwent HD-MTX therapy. Those with a Cmean(1−6) > 768 µmol/L had significantly longer overall survival (OS) (p = 0.010) and tended to have longer event-free survival (EFS) (p = 0.061), with a 5-year survival rate as high as 92.9% (p = 0.077). In contrast, prolonged OS, EFS, and 5-year survival rates were observed in patients with Cmax >936 µmol/L, but none of these differences were significant (p = 0.088, 0.200, and 0.103, respectively). Moreover, OS and EFS improved for Cmean(1−6) > 768 µmol/L regardless of Cmax. In a subgroup analysis of 24 patients aged < 20 years, OS and EFS were significantly prolonged in patients with a Cmean(1−6) > 768 µmol/L (p = 0.010 and 0.025, respectively).
conclusionsThe usefulness of the serum MTX concentration was demonstrated by designing dosing using the PK method. Furthermore, Cmean(1−6) contributed more to prolonging OS and EFS than Cmax.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.